CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Image-Guided Minimally Invasive Spinal Decompression (IG-MLD / mild®) Coverage Criteria

Governs coverage and medical necessity determinations for percutaneous image-guided minimally invasive spinal decompression (including the mild® procedure) for lumbar, cervical, and thoracic spinal stenosis, with distinctions for Medicare Advantage plans.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyImage-Guided Minimally Invasive Spinal Decompression (IG-MLD / mild®) Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateOct 1, 2015

Next Review DateN/A

Key ActionFor Medicare Advantage members, PILD is covered only within a CMS-approved clinical trial and claims in trials must use appropriate Q0/Q1 modifiers.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2015-10-01effective date published

2022-07-06policy last updated

MiDAS ENCORE n=302largest RCT cited

2014-01-09CMS CED effective

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Commercial Products — Coverage Determination

Covered when ALL of the following are met:

Commercial stance: Image-guided minimally invasive spinal decompression (cervical, thoracic, and lumbar) is considered not medically necessary due to insufficient evidence of improvement in net health outcome.

See discussion of evidence and regulatory status in chunks 11 and 12.

inv-02: Medicare Advantage Plans — Coverage Determination

Covered when ANY of the following are met:

Medicare Advantage stance: Percutaneous image-guided lumbar decompression (PILD) is covered only when provided as part of a CMS‑approved clinical study (Coverage with Evidence Development). Image-guided minimally invasive spinal decompression for cervical and thoracic regions is not covered.

See CMS CED coverage and allowed codes/modifiers in chunk 13; Medicare Advantage policy distinctions in chunk 4.

The IG-MLD devices and procedure are intended specifically for central lumbar spinal stenosis and are not intended for use near the lateral neural elements or for disc procedures. The mild® instrument kit performs tissue resection at perilaminar and interlaminar spaces and remains dorsal to the dura under image guidance; it cannot address nerve root compression or disc herniation. These limitations are contraindications to using IG-MLD when lateral neural element decompression or disc work is required.

For Commercial products, image-guided minimally invasive spinal decompression (cervical, thoracic, and lumbar) is considered not medically necessary. The policy concludes that the available evidence — including a large unblinded RCT and smaller studies — is insufficient to determine that the technology results in an improvement in net health outcome, and therefore IG-MLD is not supported for commercial coverage.

For Medicare Advantage members, the policy distinguishes lumbar procedures eligible only within CMS Coverage with Evidence Development (CED) trials and states that IG-MLD for cervical and thoracic regions is not covered.

Coding and Billing Codes

Allowed/Permitted for Medicare Advantage in CMS-approved clinical trialCPTCovered

0275T	Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral; lumbar
G0276	Blinded procedure for lumbar stenosis, percutaneous image-guided lumbar decompression (PILD) or placebo-control, performed in an approved coverage with evidence development (CED) clinical trial

Not medically necessary (Commercial products)CPTNot Covered

0275T	Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral; lumbar
G0276	Blinded procedure for lumbar stenosis, percutaneous image-guided lumbar decompression (PILD) or placebo-control, performed in an approved coverage with evidence development (CED) clinical trial

Not covered for Medicare Advantage / Not medically necessary for CommercialCPTNot Covered

0274T

Percutaneous laminotomy/laminectomy (intralaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy) any method under indirect image guidance (eg, fluoroscopic, CT), with or without the use of an endoscope, single or multiple levels, unilateral or bilateral; cervical or thoracic

Billing Modifiers for Clinical TrialsModifier

Q0	Investigational clinical service provided in a clinical research study that is in an approved research study
Q1	Routine clinical service provided in a clinical research study that is in an approved clinical research study

Provider Actions and Billing Guidance

Prior Authorization

Prior authorization — Not applicable

Not applicable — this policy does not specify any prior authorization requirements for IG-MLD or PILD.

Step Therapy

Step therapy / comparative treatments — Not applicable

Not applicable — the policy does not impose step therapy. Although trials compared IG-MLD with epidural steroid injections, no step therapy or mandated trial-of-therapy sequence is specified.

Documentation Required

Clinical study billing modifiers (Q0 / Q1)

When services are provided as part of a CMS-approved clinical study, claims must include the appropriate CMS clinical trial billing modifier: Q0 for investigational clinical services or Q1 for routine clinical services in an approved study.

Modifier Q0 — Investigational clinical service provided in an approved clinical research study (Medicare claims filed without Q0 will deny as not medically necessary).
Modifier Q1 — Routine clinical service provided in an approved clinical research study.

Denial Risk

Billing and denial triggers — Codes with high denial risk

Commercial denial risk: IG-MLD procedure codes 0275T and G0276 are listed as not medically necessary for Commercial products; code 0274T is not covered for Medicare Advantage and is also not medically necessary for Commercial products — claims billed with these codes for Commercial members risk denial.

0275T — listed as not medically necessary for Commercial products.
G0276 — listed as not medically necessary for Commercial products.
0274T — not covered for Medicare Advantage and not medically necessary for Commercial products; billing for cervical or thoracic IG-MLD will not be covered.

Background

Lumbar spinal stenosis (LSS) is commonly caused by degenerative changes such as ligamentum flavum hypertrophy and facet arthropathy leading to narrowing of the central spinal canal and symptoms of neurogenic claudication. Conventional surgical decompression (eg, laminectomy or laminotomy) is an established treatment to relieve central canal compression and improve pain and function.

The percutaneous IG-MLD (mild®) procedure is a fluoroscopically guided, ultra–minimally invasive technique that uses a specialized cannula and single-use instruments to resect hypertrophied ligamentum flavum and small amounts of lamina to decompress the central canal. The procedure is performed under fluoroscopic visualization (without endoscopic or microscopic visualization) and is intended only for central stenosis; it does not treat nerve root compression from lateral recess or foraminal stenosis, nor disc herniation.

Definitions

Image-guided minimally invasive decompression (IG-MLD) / mild® — device and procedural definition

Procedure typePercutaneous, fluoroscopy-guided decompression of the central spinal canal using a specialized cannula and single-use mild® tools to resect hypertrophied ligamentum flavum and small laminar bone.

Intended indicationCentral lumbar spinal stenosis due to ligamentum flavum hypertrophy; not intended for lateral neural elements or disc procedures.

Guidance and visualizationPerformed solely under fluoroscopic (indirect image) guidance without endoscopic or microscopic visualization; contrast may be injected into the epidural space to aid visualization.

Device componentsSpecialized cannula (eg, 6-gauge) and single-use instruments from the mild® kit (portal cannula, surgical guide, bone rongeur, tissue sculpter, trocar).

Anatomic limitations / contraindicationsDevice and procedure are not intended for use near lateral neural elements and are contraindicated for disc procedures; cannot address nerve root compression or disc herniation.

PILD (Percutaneous Image-Guided Lumbar Decompression) — CMS/CED term definition

CMS terminologyPercutaneous Image-Guided Lumbar Decompression (PILD) is the term used in the CMS Coverage with Evidence Development (CED) decision for percutaneous laminotomy/laminectomy procedures performed under indirect image guidance as part of an approved clinical study.

Medicare Advantage coverage contextEffective January 9, 2014, CMS determined PILD is covered by Medicare only when provided in an approved CED clinical study for beneficiaries with lumbar spinal stenosis.

Relevant CPT / HCPCS codes (CED)0275T: percutaneous laminotomy/laminectomy (interlaminar approach), lumbar; G0276: blinded PILD or placebo-control in an approved CED trial.

Billing modifiers for CED studiesClaims for services in a CMS-approved clinical study must be billed with modifier Q0 (investigational clinical service) or Q1 (routine clinical service) per CMS guidance.